Rakovina Therapeutics Inc RKV
TSXV · Canada · Finance
CAD 0.2500+0.01 (+2.04%)
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CAD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor programVANCOUVER, British Columbia, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced a research collaboration with Boston-based Celvion Therapeutics (“Celvion”) to leverage Celvion’s proprietary EM
Yale physician-scientist and biotech entrepreneur Dr. Ranjit Bindra brings deep expertise in DNA repair, synthetic lethality and brain tumor therapeuticsVANCOUVER, British Columbia, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Dr. Ranjit Bindra, MD, PhD, to its Scientific Advisory Board (“SAB”). Dr. Bindra is the Scienti
Chair of Translational Neuro-Oncology at the University of Manchester, previously a member of the Company's Scientific Advisory Board, elected at the 2026 Annual General MeetingVANCOUVER, British Columbia, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing innovative cancer therapies through AI-powered drug discovery, today announced the appointment of Prof. Petra Hamerlik to its board of directors at the Company’s annual
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.